Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours

European Journal of Cancer

Volumn 38, Issue 12, 2002, Pages 1564-1579

  Vermeulen, P B ^a,j   Gasparini, G ^b   Fox, S B ^c   Colpaert, C ^a   Marson, L P ^d   Gion, M ^e   Belien J A M ^f   De Waal, R M W ^g   Van Marck, E ^a   Magnani, E ^b   Weidner, N ^h   Harris, A L ⁱ   Dirix, L Y ^j  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^e Centre for the Study of Biological Markers of Malignancy   (Italy)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^j SINT AUGUSTINUS HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; FIBRONECTIN; GELATINASE B; INTEGRIN; MESSENGER RNA; MONOCLONAL ANTIBODY; UROKINASE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; CANCER TISSUE; CELL PROLIFERATION; DISEASE MARKER; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; SOLID TUMOR; TISSUE DIFFERENTIATION; TISSUE SECTION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 0036345395     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00094-1     Document Type: Article

References (143)

1. Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation
2. What is the evidence that tumors are angiogenesis dependent?
3. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis
4. Angiogenesis in primary lung cancer and lung secondaries
5. New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
6. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia
7. Biological characterization of subgroups of squamous cell lung carcinomas
8. Vasculogenic mimicry: How convincing, how novel, and how significant
9. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
10. Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood
11. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
12. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
13. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells
14. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: A novel mechanism of tumor angiogenesis
15. Prognostic factors in breast cancer. College of American pathologists consensus statement 1999
16. Homologous up-regulation of KDR/Flk-1 receptor by vascular endothelial growth factor in vitro
17. Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma
18. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
19. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39
20. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer
21. Early and extensive contribution of pericytes/vascular smooth muscle cells to microvascular proliferation in glioblastoma multiforme: An immuno-light and immuno-electron microscopic study
22. The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium
23. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer
24. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: Correlation with Gleason's score, microvessel density, and epithelial cell proliferation
25. Correlation of the fractions of proliferating tumor and endothelial cells in breast and colorectal adenocarcinoma is independent of tumor histiotype and microvessel density
26. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms
27. Integrin-alpha-v-beta-3 requirement for sustained mitogen-activated protein-kinase activity during angiogenesis
28. Intratumoral microvessel density and expression of ED-A/ED-B sequences of fibronectin in breast carcinoma
29. A high-affinity human antibody that targets tumoral blood vessels
30. Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis
31. Vascular endothelial growth factor as a marker of tumor endothelium
32. Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: Correlation with p53 and angiogenic factor expression
33. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor
34. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
35. Genes expressed in human tumor endothelium
36. Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer
37. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
38. Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma
39. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
40. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
41. Heterogeneous vascular dependence of tumor cell populations
42. Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis
43. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients
44. Different patterns of angiogenesis in sarcomas and carcinomas
45. Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer
46. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
47. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
48. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
49. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
50. Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: Relation to bcl-2 expression, hormone receptors, and lymph node metastases
51. Fibrotic focus in invasive ductal carcinoma: An indicator of high tumor aggressiveness
52. Optimizing microvessel counts according to tumor zone in invasive ductal carcinoma of the breast
53. Early distant relapse in "node negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour
54. Intratumoural hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph-node negative breast cancer patients
55. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases
56. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages
57. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: Its impact on prognosis and on response to chemotherapy
58. Tumor vascularity: A histological measure of angiogenesis and hypoxia
59. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma
60. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients
61. Serum vascular endothelial growth factor is often elevated in disseminated cancer
62. Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy
63. Serum vascular endothelial growth factor levels in various liver diseases
64. Vascular endothelial cell growth factor (VEGF) serum concentrations change according to the phase of the menstrual cycle
65. Circulating vascular endothelial growth factor in patients with colorectal cancer
66. Vascular endothelial growth factor in premenopausal women - Indicator of the best time for breast cancer surgery?
67. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer
68. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer
69. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer
70. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer
71. Serum vascular endothelial growth factor (VEGF) in the normal menstrual cycle: Association with changes in ovarian and uterine Doppler blood flow
72. Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma
73. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas
74. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: Relationship with prognostic variables and clinical outcome
75. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma
76. Serum concentrations of vascular endothelial growth factor in vulvar cancer
77. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease
78. Diagnostic value of serum VEGF in women with ovarian tumors
79. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients
80. Serum VEGF levels in women with a benign breast tumor or breast cancer
81. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma
82. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum and tissue VEGF and microvessel density and effects of tamoxifen
83. Clinical implications of circulating angiogenic factors in cancer patients
84. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in patients with advanced colorectal cancer
85. Elevated levels of the angiogenic cytokines bFGF and VEGF in sera of cancer patients
86. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients
87. Platelet: Transporter of vascular endothelial growth factor
88. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
89. In vitro release of vascular endothelial growth factor during platelet aggregation
90. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: Implications for measurement of circulating VEGF levels in clinical disease
91. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor
92. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patiens and volunteers: A key to study an angiogenic marker in vivo
93. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral Blood
94. Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study
95. Validation of blood collection procedures for the determination of circulating vascular endothelial grow factor (VEGF) in different blood compartments
96. Cytosol vascular endothelial growth factor in endometrial carcinoma: Correlation with disease-free survival
97. Quantitative analysis of vascular endothelial growth factor in primary breast cancer
98. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
99. Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: Prognostic implications
100. Clinical relevance of vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) in patients with node-positive breast cancer treated either with adjuvant chemotherapy or hormonetherapy
101. Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
102. Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival
103. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factors, tumor growth factor β-1, platelet-derived endothelial growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis
104. Markers of tumor angiogenesis and proteolysis independent define high- and low-risk subsets of node-negative cancer patients
105. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
106. P53 and vascular endothelial growth factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma
107. Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?
108. Vascular endothelial growth factor: a further prognostic factor in node-negative breast cancer?
109. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer
110. Angiogenesis: Pathological, prognostic, and growth factor pathways and their link to trial design and anticancer drugs
111. Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy
112. Clinical implications of circulating angiogenic factors in cancer patients
113. Tumor vascularity is not a prognostic factor for malignant melanoma of the skin
114. Tumour vascularity is not a prognostic factor for cutaneous melanoma
115. Tumor angiogenesis, the p53 antigen, and cervical metastasis in squamous carcinoma of the tongue
116. Intratumoral microvessel density as a prognostic factor in cancer
117. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development
118. Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3
119. Expression of the vascular endothelial growth factor c receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors
120. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing
121. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors
122. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
123. Angiogenesis and lymphangiogenesis in stage 1 germ cell tumours of the testis
124. Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer
125. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers
126. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries. Podoplanin as a specific marker for lymphatic endothelium
127. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells
128. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis
129. Anatomic distribution of intraprostatic lymphatics: Implications for the lymphatic spread of prostate cancer - A preliminary study
130. Histochemical localization of 5′-nucleotidase in the lymphatic endothelium
131. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
132. The histochemical distribution of 5-nucleotidase and unspecific alkaline phosphatase in the testicle of various species and two human seminomas
133. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan
134. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3
135. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
136. Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer
137. Lack of lymphangiogenesis in human primary cutaneous melanoma: Consequences for the mechanism of lymphatic dissemination
138. Lack of lymphangiogenesis despite coexpression of vegf-c and its receptor flt-4 in uveal melanoma
139. Patterns of HER2/NEU amplification in primary and metastatic breast cancer
140. Non-invasive PET imaging of ER expression in breast cancer: Sex steroid binding protein (SBG or SHBG) interaction and ER expression heterogeneity
141. Reproducibility of microvessel counts in breast cancer specimens
142. Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumour?
143. Linking gene expression patterns to therapeutic groups in breast cancer